百济神州(06160)下跌5.01%,报115.7元/股

金融界
13 Nov 2024

11月13日,百济神州(06160)盘中下跌5.01%,截至10:51,报115.7元/股,成交1.06亿元。

百济神州有限公司是一家专注于开发和商业化用于治疗癌症的创新型分子靶向和肿瘤免疫治疗药物的生物技术公司。公司拥有包括六种内部开发的临床阶段候选药物和五种获得授权许可的药物在内的广泛产品组合,以及超过1300名员工的全球团队。

截至2024年三季报,百济神州营业总收入187.97亿元、净利润-34.54亿元。

11月12日,2024财年三季报归属股东应占溢利-4.929亿美元,同比增长4.13%,基本每股收益-0.36美元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10